Signalling networks that cause cancer

Trends in Biochemical Sciences

Volumn 24, Issue 12, 1999, Pages

  McCormick, Frank ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; RAS PROTEIN;

APOPTOSIS; CANCER; CANCER INHIBITION; CELL CYCLE; COLON POLYPOSIS; COLORECTAL CANCER; GENE MUTATION; HUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0033435103     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0004(99)01480-2     Document Type: Review

References (36)

1. Campbell S.L.et al. Increasing complexity of Ras signalling. Oncogene. 17:1998;1395-1413.
2. Irigoyen J.P.et al. Cytoskeleton reorganization induces the urokinase-type plasminogen activator gene via the Ras/extracellular signal-regulated kinase (ERK) signalling pathway. J. Biol. Chem. 272:1997;1904-1909.
3. Milanini J.et al. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J. Biol. Chem. 273:1998;18165-18172.
4. Gille H., Downward J. Multiple ras effector pathways contribute to G(1) cell cycle progression. J. Biol. Chem. 274:1999;22033-22040.
5. Qiu R.G.et al. An essential role for Rac in Ras transformation. Nature. 374:1995;457-459.
6. Qiu R.G.et al. A role for Rho in Ras transformation. Proc. Natl. Acad. Sci. U. S. A. 92:1995;11781-11785.
7. Verheijen M.H.et al. Interdependent action of RalGEF and Erk in Ras-induced primitive endoderm differentiation of F9 embryonal carcinoma cells. Oncogene. 18:1999;4435-4439.
8. van Weering D.H.et al. Protein kinase B activation and lamellipodium formation are independent phosphoinositide 3-kinase-mediated events differentially regulated by endogenous Ras. Mol. Cell. Biol. 18:1998;1802-1811.
9. Balmain A. Target genes and target cells in carcinogenesis. Br. J. Cancer. 80:1999;28-33.
10. Kauffmann-Zeh A.et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 385:1997;544-548.
11. Datta S.R.et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:1997;231-241.
12. Cardone M.H.et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 282:1998;1318-1321.
13. Brunet A.et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 96:1999;857-868.
14. Kops G.J.et al. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature. 398:1999;630-634.
15. Maehama T., Dixon J.E. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 9:1999;125-128.
16. Haas-Kogan D.et al. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol. 8:1998;1195-1198.
17. Polakis P. The oncogenic activation of β-catenin. Curr. Opin. Genet. Dev. 9:1999;15-21.
18. He T.C.et al. Identification of c-MYC as a target of the APC pathway. Science. 281:1998;1509-1512.
19. Tetsu O., McCormick F. β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 398:1999;422-426.
20. Crawford H.C.et al. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumours. Oncogene. 18:1999;2883-2891.
21. Mann B.et al. Target genes of β-catenin-T cell-factor/lymphoid-enhancer-factor signalling in human colorectal carcinomas. Proc. Natl. Acad. Sci. U. S. A. 96:1999;1603-1608.
22. Howe L.R.et al. Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells. Cancer Res. 59:1999;1572-1577.
23. Bullions L.C., Levine A.J. The role of β-catenin in cell adhesion, signal transduction, and cancer. Curr. Opin. Oncol. 10:1998;81-87.
24. Lavoie J.N.et al. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem. 271:1996;20608-20616.
25. Diehl J.A.et al. Glycogen synthase kinase-3 β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12:1998;3499-3511.
26. Gille H., Downward J. Multiple ras effector pathways contribute to G(1) cell cycle progression. J. Biol. Chem. 274:1999;22033-22040.
27. Wu X.et al. The p53-MDM2 autoregulatory feedback loop. Genes Dev. 7:1993;1126-1132.
28. Fambrough D.et al. Diverse signalling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes. Cell. 97:1999;727-741.
29. Sun P.et al. p53-independent role of MDM2 in TGF-β 1 resistance. Science. 282:1998;2270-2272.
30. Elkeles A.et al. The c-fos proto-oncogene is a target for transactivation by the p53 tumor suppressor. Mol. Cell. Biol. 19:1999;2594-2600.
31. Sears R.et al. Ras enhances Myc protein stability. Mol. Cell. 3:1999;169-179.
32. Damalas A.et al. Excess β-catenin promotes accumulation of transcriptionally active p53. EMBO J. 18:1999;3054-3063.
33. Zhu J.et al. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12:1998;2997-3007.
34. Kowalik T.F.et al. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J. Virol. 69:1995;2491-2500.
35. Weinstein I.B.et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin. Cancer Res. 3:1997;2696-2702.
36. Pinkel D.et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat. Genet. 20:1998;207-211.